NR3C2 and Hyperkalemia: Preliminary studies showed that lower doses of finerenone were needed to achieve similar cardiovascular and renal effects compared to steroidal mineralocorticoid receptor antagonists (spironolactone and eplerenone), and induced less hyperkalemia.